Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Shares Outstanding (2023 - 2025)

Immunome's Shares Outstanding history spans 3 years, with the latest figure at $113.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 75.51% year-over-year to $113.1 million; the TTM value through Dec 2025 reached $113.1 million, up 75.51%, while the annual FY2025 figure was $113.1 million, 75.51% up from the prior year.
  • Shares Outstanding reached $113.1 million in Q4 2025 per IMNM's latest filing, up from $91.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $113.1 million in Q4 2025 to a low of $12.2 million in Q1 2023.
  • Average Shares Outstanding over 3 years is $58.6 million, with a median of $60.2 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding: surged 395.16% in 2024, then soared 44.99% in 2025.
  • A 3-year view of Shares Outstanding shows it stood at $43.3 million in 2023, then skyrocketed by 49.04% to $64.5 million in 2024, then soared by 75.51% to $113.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Shares Outstanding are $113.1 million (Q4 2025), $91.7 million (Q3 2025), and $87.0 million (Q2 2025).